What is EQUIMUNE I.V. 1.5 ml Syringe?
EQUIMUNE® I.V. is an immunotherapeutic agent for the treatment of Equine Respiratory Disease Complex, (ERDC). The common causes of ERDC are equine herpesvirus (rhinopneumonitis), influenza A equine 1 and influenza A equine 2.
Who is it for?
Why use it?
EQUIMUNE® I.V. is indicated in those conditions where immunotherapy will enhance the immune response to respiratory tract infections. Efficacy of EQUIMUNE® I.V. is not altered by concurrent use of antibiotics.
How it works?
Mycobacterium cell wall compounds have immunomodulating activity. EQUIMUNE® I.V. is an emulsion of purified mycobacterium cell walls which have been extracted by a process which reduces their toxic and allergic effects, but retains their immunostimulating activity.
EQUIMUNE® I.V. activates antigen presenting cells thereby enhancing the production of the polypeptide cytokine interleukin 1 (lL-1).
Bioniche Animal Health
Mycobacterium cell wall fraction immunostimulant.
How is it sold?
Equimune I.V. 1.5 ml Syringe
What are the side effects?
Mild fever, drowsiness, and an increased catabolic rate leading to decreased appetite may occur for one to two days following an EQUIMUNE® I.V. injection.
What special precautions are there?
It is important to ensure that the emulsion remains thoroughly mixed during injections. Use the entire contents when first opened. Discard remaining portions.
What to do if overdose?
Contact your nearest emergency animal clinic.
How Can I store it?
Store at 36-45°F (2-7°C). Do not freeze.
Cortisone reduces the production of lL-1.1 Horses being treated with corticosteroids or ACTH may not respond to EQUIMUNE® I.V. therapy.
Dosage and Administration: For intravenous use only.
The recommended dose for immunostimulation is 1.5 mL (1 syringe) by intravenous injection into the jugular vein. Treatment may be repeated in one (1) to three (3) weeks.
1. Observe aseptic techniques when injecting animals.
2. In the event of an anaphylactic reaction, administer epinephrine.
Active Ingredient(s): Mycobacterium cell wall fraction immunostimulant.
Indications: An immunotherapeutic agent for the treatment of Equine Respiratory Disease Complex, (ERDC). The common causes of ERDC are equine herpesvirus (rhinopneumonitis), influenza A equine 1 and influenza A equine 2.
Toxicology: Safety: EQUIMUNE® I.V. is safe to use in pregnant mares. Other than the contraindications listed above, EQUIMUNE® I.V. is compatible with standard treatment and vaccination regimes.
Viral diseases are a common problem when it comes horses. Most commonly these are respiratory tract viruses that can cause severe inflammation and damage to the upper and lower respiratory tracts. However there are many other viral diseases that horses are exposed to and that can cause a wide range of clinical signs and outcomes. At best there may be slight decrease in performance or in more severe cases expensive veterinary treatment or even death.
There are limited treatments available that can be used to prevent or minimize clinical signs of viral disease. One product that may be useful is Equimune® I.V. This is a purified extract of a portion of the cell wall of bacteria which has been processed to reduce any toxic or allergic side effects but which still retains the ability to produce an immune response. Following injection of Equimune® intravenously the hoses body will recognize a foreign protein is present and mounts an immune response, primarily through activation of cytokine interleukin. This immune response is similar to that which would occur following a natural viral or bacterial infection and effectively prepares the immune system for when a real viral infection occurs.